EGF-liposomes promote efficient EGFR targeting in xenograft colocarcinoma model
Sara Zalba1,2, Ana Margarita Contreras1, María Merino1
1Department of Pharmacy & Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, Spain.
Aim:
Development of EGF-liposomes (LP-EGF) for selective molecules delivery in tumors expressing EGFR.
Material & Methods:
In vitro cellular interaction of EGF-LP and nontargeted liposomes (LP-N) was assayed at 37 and 4 °C in cells expressing different EGFR levels. Receptor-mediated uptake was investigated by competition with a monoclonal antibody anti-EGFR. Selective intracellular drug delivery and efficacy was tested by oxaliplatin encapsulation. In vivo biodistribution of LP-N and LP-EGF was done in xenograft model.
Results:
LP-EGF was internalized by an active and selective mechanism through EGFR without receptor activation. Oxaliplatin LP-EGF decreased IC50 between 48 and 13% in cell EGFR+. LP-EGF was accumulated in tumor over 72 h postdosing, while LP-N in spleen.
Conclusion:
LP-EGF represents an attractive nanosystem for cancer therapy or diagnosis.
More Related Videos
07:50Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts
Published on: May 25, 2018
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020